An advisory panel did not recommend Thursday that the Food and Drug Administration approve a leukemia-fighting drug from Astex Pharmaceuticals Inc. and partner Eisai Co. Ltd.
The FDA’s oncology advisory committee voted 10-3 against recommending that Dacogen be approved for elderly patients with acute myeloid leukemia. One member abstained.
The recommendation is not binding, but the FDA typically follows a panel’s decision.
The FDA is scheduled to make its final decision March 6.